180 related articles for article (PubMed ID: 29235566)
1. Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity.
Reddy SM; Barcenas CH; Sinha AK; Hsu L; Moulder SL; Tripathy D; Hortobagyi GN; Valero V
Br J Cancer; 2018 Jan; 118(1):17-23. PubMed ID: 29235566
[TBL] [Abstract][Full Text] [Related]
2. Location of Receipt of Initial Treatment and Outcomes in Long-Term Breast Cancer Survivors.
Sinha AK; Patel JR; Shen Y; Ueno NT; Giordano SH; Tripathy D; Lopez DS; Barcenas CH
PLoS One; 2017; 12(1):e0170081. PubMed ID: 28085940
[TBL] [Abstract][Full Text] [Related]
3. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
[TBL] [Abstract][Full Text] [Related]
4. Is conservative surgery a good option for patients with "triple negative" breast cancer?
Martinez-Ramos D; Escrig-Sos J; Torrella-Ramos A; Alcalde-Sanchez M; Salvador-Sanchis JL
Breast; 2012 Jun; 21(3):401-5. PubMed ID: 22579462
[TBL] [Abstract][Full Text] [Related]
5. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
Barcenas CH; Raghavendra A; Sinha AK; Syed MP; Hsu L; Patangan MG; Chavez-MacGregor M; Shen Y; Hortobagyi GH; Valero V; Giordano SH; Ueno NT; Tripathy D
Cancer; 2017 Jul; 123(13):2422-2431. PubMed ID: 28199747
[TBL] [Abstract][Full Text] [Related]
6. Breast-conserving therapy for triple-negative breast cancer.
Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
[TBL] [Abstract][Full Text] [Related]
7. Prognostic relevance of biological subtype overrides that of TNM staging in breast cancer: discordance between stage and biology.
Jung HA; Park YH; Kim M; Kim S; Chang WJ; Choi MK; Hong JY; Kim SW; Kil WH; Lee JE; Nam SJ; Ahn JS; Im YH
Tumour Biol; 2015 Feb; 36(2):1073-9. PubMed ID: 25326808
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Risk of Recurrence by Subtype in ≤ 1-cm Breast Tumors.
Colonna SV; Higgins AK; Alvarez J; Saville BR; Lawrence J; Abramson VG
Clin Breast Cancer; 2016 Jun; 16(3):223-31. PubMed ID: 26683741
[TBL] [Abstract][Full Text] [Related]
9. Long-term Survival in Breast Cancer Patients Is Associated with Contralateral Parenchymal Enhancement at MRI: Outcomes of the SELECT Study.
Ragusi MAA; van der Velden BHM; Meeuwis C; Tetteroo E; Coerkamp EG; van Nijnatten TJA; Jansen FH; Wolters-van der Ben EJM; Jongen L; van Raamt F; Dorrius MD; Verloop J; Viergever MA; Pijnappel RM; Elias SG; Gilhuijs KGA
Radiology; 2023 May; 307(4):e221922. PubMed ID: 36975820
[TBL] [Abstract][Full Text] [Related]
10. Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer.
Tsai J; Bertoni D; Hernandez-Boussard T; Telli ML; Wapnir IL
Ann Surg Oncol; 2016 Oct; 23(10):3310-6. PubMed ID: 27401442
[TBL] [Abstract][Full Text] [Related]
11. Risk factors of recurrence in small-sized, node negative breast cancer in young women: a retrospective study in Chinese population.
Zhang X; Li P; Ma W; Di W; Zhao S; Gao Q; Zhao Y; Yang M; Zhang Q
Sci China Life Sci; 2013 Apr; 56(4):335-40. PubMed ID: 23483340
[TBL] [Abstract][Full Text] [Related]
12. Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype.
Theriault RL; Litton JK; Mittendorf EA; Chen H; Meric-Bernstam F; Chavez-Macgregor M; Morrow PK; Woodward WA; Sahin A; Hortobagyi GN; Gonzalez-Angulo AM
Clin Breast Cancer; 2011 Oct; 11(5):325-31. PubMed ID: 21764391
[TBL] [Abstract][Full Text] [Related]
13. Risk of Recurrence or Contralateral Breast Cancer More than 5 Years After Diagnosis of Hormone Receptor-Positive Early-Stage Breast Cancer.
Wilson S; Speers C; Tyldesley S; Chia S; Kennecke H; Ellard S; Lohrisch C
Clin Breast Cancer; 2016 Aug; 16(4):284-90. PubMed ID: 26705158
[TBL] [Abstract][Full Text] [Related]
14. An overview of triple-negative breast cancer.
Kumar P; Aggarwal R
Arch Gynecol Obstet; 2016 Feb; 293(2):247-69. PubMed ID: 26341644
[TBL] [Abstract][Full Text] [Related]
15. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer?
Parker CC; Ampil F; Burton G; Li BD; Chu QD
Surgery; 2010 Aug; 148(2):386-91. PubMed ID: 20580045
[TBL] [Abstract][Full Text] [Related]
16. cMET and phospho-cMET protein levels in breast cancers and survival outcomes.
Raghav KP; Wang W; Liu S; Chavez-MacGregor M; Meng X; Hortobagyi GN; Mills GB; Meric-Bernstam F; Blumenschein GR; Gonzalez-Angulo AM
Clin Cancer Res; 2012 Apr; 18(8):2269-77. PubMed ID: 22374333
[TBL] [Abstract][Full Text] [Related]
17. Clinical and pathological response to neoadjuvant chemotherapy based on primary tumor reduction is correlated to survival in hormone receptor-positive but not hormone receptor-negative locally advanced breast cancer.
Chen S; Liu Y; Ouyang QW; Huang L; Luo RC; Shao ZM
Ann Surg Oncol; 2015 Jan; 22(1):32-9. PubMed ID: 25012266
[TBL] [Abstract][Full Text] [Related]
18. Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
Leon-Ferre RA; Jonas SF; Salgado R; Loi S; de Jong V; Carter JM; Nielsen TO; Leung S; Riaz N; Chia S; Jules-Clément G; Curigliano G; Criscitiello C; Cockenpot V; Lambertini M; Suman VJ; Linderholm B; Martens JWM; van Deurzen CHM; Timmermans AM; Shimoi T; Yazaki S; Yoshida M; Kim SB; Lee HJ; Dieci MV; Bataillon G; Vincent-Salomon A; André F; Kok M; Linn SC; Goetz MP; Michiels S;
JAMA; 2024 Apr; 331(13):1135-1144. PubMed ID: 38563834
[TBL] [Abstract][Full Text] [Related]
19. Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system.
Fehrenbacher L; Capra AM; Quesenberry CP; Fulton R; Shiraz P; Habel LA
J Clin Oncol; 2014 Jul; 32(20):2151-8. PubMed ID: 24888815
[TBL] [Abstract][Full Text] [Related]
20. A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery.
Park YH; Jung HH; Do IG; Cho EY; Sohn I; Jung SH; Kil WH; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH
Int J Cancer; 2015 Apr; 136(8):1976-84. PubMed ID: 25537444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]